Who founded IgGenix Inc.?

IgGenix Inc. was founded by Kari Nadeau in 2019.

Who are IgGenix Inc.'s investors?

IgGenix Inc.'s investors include Khosla Ventures, Allerfund Ventures, Llc, FemHealth Ventures, Global Brain, Medical Incubator Japan K.K., ShangBay Capital LLC, Alexandria, SBI Investment.

Where is IgGenix Inc. headquartered?

IgGenix Inc. is headquartered in South San Francisco, US.

IgGenix Inc.

South San Francisco, US · Founded 2019 · 8 employees on LinkedIn · 8 known investors

Find your way into IgGenix Inc.

Your email: who you already know at IgGenix Inc., and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the IgGenix Inc. team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases. The company uses its proprietary SEQ SIFTER™ platform to develop first-in-class therapeutic antibodies targeting allergic cascades.

AI & Machine Learning Biotech Healthtech

Founders & leadership

IgGenix Inc. was founded in 2019 by Kari Nadeau.

Kari NadeauScientific Co-Founder

Investors · 8

Khosla Ventures✓ confirmed by IgGenix Inc.Menlo Park · $100K – $20M

How we know: the company's own site · press coverage · Not right? Tell us

Allerfund Ventures, Llclisted by Allerfund Ventures, LlcNew York

How we know: Allerfund Ventures, Llc's portfolio page · Not right? Tell us

FemHealth Ventureslisted by FemHealth VenturesShort Hills

How we know: FemHealth Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Global Brainlisted by Global BrainTokyo · $100K

How we know: Global Brain's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Medical Incubator Japan K.K.listed by Medical Incubator Japan K.K.Tokyo

ShangBay Capital LLClisted by ShangBay Capital LLCPalo Alto

How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us

AlexandriareportedPasadena

How we know: press coverage · Not right? Tell us

SBI InvestmentreportedTokyo

How we know: funding news · Not right? Tell us

Related companies · 5

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

arGEN-XThe company develops therapies for people with severe autoimmune diseases.

PhigenixPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.

OrigeneOriGene develops and manufactures research and diagnostic products, including large-scale GMP antibody production, with R&D and research manufacturing operations. It serves the life sciences and biotech research market from facilities in the US and Germany.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as IgGenix Inc..

In the news

IgGenix Holds First Close of $40M Series B Financing - FinSMEsfinsmes.com · Feb 2023

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy - BioSpacebiospace.com · Feb 2023

Frequently asked questions

What does IgGenix Inc. do?: IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases. The company uses its proprietary SEQ SIFTER™ platform to develop first-in-class therapeutic antibodies targeting allergic cascades.
Who founded IgGenix Inc.?: IgGenix Inc. was founded by Kari Nadeau in 2019.
Who are IgGenix Inc.'s investors?: IgGenix Inc.'s investors include Khosla Ventures, Allerfund Ventures, Llc, FemHealth Ventures, Global Brain, Medical Incubator Japan K.K., ShangBay Capital LLC, Alexandria, SBI Investment.
Where is IgGenix Inc. headquartered?: IgGenix Inc. is headquartered in South San Francisco, US.